Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer

Bookmark and Share
Published: 1 Jun 2014
Views: 4686
Dr Olivia Pagani - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Dr Pagani talks to ecancertv at ASCO 2014 about the results of a landmark study that was a joint analysis of two phase III trials, TEXT and SOFT, which demonstrated that the aromatase inhibitor exemestane more effectively prevents breast cancer recurrences than tamoxifen when given with ovarian function suppression in premenopausal women with hormone-sensitive cancers.

Read the article or watch the press conference for more.

ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.